AGP Picks
View all

Health Times of Rhode Island
Provided by AGP

Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on September 30, 2026

DiFusion Activates Operating Board to Scale Therapeutic Biomaterials Platform
Sep. 30, 2026

DiFusion Activates Operating Board to Scale Therapeutic Biomaterials Platform

Indeterminate GlobeNewswire
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
Sep. 30, 2026

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Indeterminate GlobeNewswire
Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure
Sep. 30, 2026

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

Indeterminate GlobeNewswire
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
Sep. 30, 2026

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

Indeterminate GlobeNewswire
Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)
Sep. 30, 2026

Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)

Indeterminate GlobeNewswire
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Sep. 30, 2026

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Indeterminate GlobeNewswire
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Sep. 30, 2026

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Indeterminate GlobeNewswire
Immutep Receives ~A$0.86 Million R&D Tax Incentive
Sep. 30, 2026

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Indeterminate GlobeNewswire
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
Sep. 30, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Indeterminate GlobeNewswire
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Sep. 30, 2026

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
Sep. 30, 2026

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Indeterminate GlobeNewswire
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Sep. 30, 2026

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Indeterminate GlobeNewswire
CURE ALZHEIMER’S FUND AWARDS $6.4 MILLION TO CARDINAL FAMILY SCHOLARS ADVANCING ALZHEIMER’S RESEARCH
Sep. 30, 2026

CURE ALZHEIMER’S FUND AWARDS $6.4 MILLION TO CARDINAL FAMILY SCHOLARS ADVANCING ALZHEIMER’S RESEARCH

Indeterminate GlobeNewswire
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Sep. 30, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Indeterminate GlobeNewswire
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Sep. 30, 2026

Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings

Indeterminate GlobeNewswire
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sep. 30, 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Indeterminate GlobeNewswire
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Sep. 30, 2026

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Indeterminate GlobeNewswire
Ocugen to Participate in Upcoming Scientific Conferences
Sep. 30, 2026

Ocugen to Participate in Upcoming Scientific Conferences

Indeterminate GlobeNewswire
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
Sep. 30, 2026

R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

Indeterminate GlobeNewswire
EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application
Sep. 30, 2026

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Times of Rhode Island

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.